

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A pharmaceutical composition comprising a liquid carrier, valdecoxib; and a cyclodextrin;

wherein the cyclodextrin is present in an amount of not less than 5%, w/v, of the composition, and

wherein at least a substantial portion of the valdecoxib is in solubilized form in the liquid carrier and wherein at a given temperature, the weight ratio of said valdecoxib in solubilized form to said cyclodextrin is in a proportion of at least about 2.5% greater than is achievable in a substantially similar composition but which comprises less than 5%, w/v, of said cyclodextrin at the given temperature.

Claim 2 (currently amended): The composition of Claim 1 wherein said cyclodextrin amount is not less than about 7.5%, w/v, of the composition.

Claim 3 (currently amended): The composition of Claim 1 wherein said cyclodextrin amount is not less than about 15%, w/v, of the composition.

Claim 4 (original): The composition of Claim 1 wherein said proportion is greater than at least about 5.0 %.

Claim 5 (original): The composition of Claim 1 wherein said proportion is greater than at least about 10.0%.

Claim 6 (currently amended): The composition of Claim 1 wherein the cyclodextrin is an α -cyclodextrin [[cylcodextrin]] and/or a β -cyclodextrin.

Claim 7 (original): The composition of Claim 1 wherein the cyclodextrin is an at least partially etherified β -cyclodextrin.

Claim 8 (original): The composition of Claim 1 wherein the cyclodextrin is a sulfoalkyl ether cyclodextrin and/or a hydroxyalkyl- β -cyclodextrin.

Claim 9 (original): The composition of Claim 1 wherein the cyclodextrin is a sulfobutyl ether cyclodextrin and/or hydroxypropyl- β -cyclodextrin.

Claim 10 (original): The composition of Claim 1 wherein the valdecoxib is present at a concentration of not less than about 1 mg/ml of the composition.

Claim 11 (original): The composition of Claim 1 wherein the valdecoxib is present at a concentration of not less than about 2 mg/ml of the composition.

Claim 12 (original): The composition of Claim 1 wherein the valdecoxib is present at a concentration of about 4 mg/ml to about 10 mg/ml.

Claim 13 (original): The composition of Claim 1 wherein the liquid carrier comprises water suitable for injection.

Claim 14 (currently amended): The composition of Claim 1 wherein (a) the valdecoxib is present at a concentration of about 4 mg/ml to about 10 mg/ml; (b) the cyclodextrin is a sulfobutyl ether cyclodextrin and/or hydroxypropyl- β -cyclodextrin; (c) said cyclodextrin amount is not less than about 7.5%, w/v, of the composition; and (d) [[.]] said proportion is greater than at least about 5.0 %.

Application Serial No. 10/721,645 [Attorney Docket No. 3598/1/US (PC31393)]
Amendment dated 9 February 2006
Reply to Office action dated 9 August 2005

Claim 15 (currently amended): **[[The]] A method of treating a disorder mediated by COX-2, said method** comprising administration of the composition of Claim 1 to a subject in need thereof.

Claim 16 (cancelled).

Claim 17 (original): The method of Claim 15 wherein said administration is once or twice daily.

Claim 18 (new): The method of Claim 15 wherein said disorder mediated by COX-2 is a disorder characterized by inflammation, pain and/or fever.

Claim 19 (new): The method of Claim 15 wherein said disorder is arthritis.